Article | October 27, 2016

Apply Novel Assays To Assess Immunogenicity Risks

Source: Lonza Biologics, Inc.
Apply Novel Essays To Assess Immunogenicity Risks

Lonza’s Epibase® In Vitro (IV) platform uses human peripheral blood mononuclear cells (PBMCs) to provide researchers with an immune response that closely resembles the response in a human. The Epibase IV assays provide fast, cost-effective ways to gain human-based immunogenicity information on candidates prior to the first human dose.